Moleculin Biotech Ownership 2024 | Who Owns Moleculin Biotech Now?
Institutional Ownership
17.39%
Insider Ownership
4.33%
Retail Ownership
78.28%
Institutional Holders
23.00
Moleculin Biotech Institutional Shareholders
Institutional Shareholders by % of Total Shares
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
JPMORGAN CHASE & CO | - | - | - | -52 | -100.00% | - | Mar 31, 2024 |
BANK OF AMERICA CORP /DE/ | - | - | - | -138 | -100.00% | - | Mar 31, 2024 |
WELLS FARGO & COMPANY/MN | - | - | - | -229 | -100.00% | - | Mar 31, 2024 |
NORTHERN TRUST CORP | - | - | - | -53,596 | -100.00% | - | Mar 31, 2024 |
STATE STREET CORP | - | - | - | -71,397 | -100.00% | - | Mar 31, 2024 |
VANGUARD GROUP INC | - | - | - | -1,080,122 | -100.00% | - | Mar 31, 2024 |
MORGAN STANLEY | - | - | - | -6,334 | -100.00% | - | Mar 31, 2024 |
ROYAL BANK OF CANADA | - | - | - | -20,148 | -100.00% | - | Mar 31, 2024 |
SCHMIDT P J INVESTMENT MANAGEMENT INC | - | - | - | -29,000 | -100.00% | - | Mar 31, 2024 |
RENAISSANCE TECHNOLOGIES LLC | - | - | - | -129,600 | -100.00% | - | Mar 31, 2024 |
GEODE CAPITAL MANAGEMENT, LLC | - | - | - | -246,670 | -100.00% | - | Mar 31, 2024 |
NORTH STAR INVESTMENT MANAGEMENT CORP. | - | - | - | -250 | -100.00% | - | Mar 31, 2024 |
BLACKROCK INC. | - | - | - | -188,924 | -100.00% | - | Mar 31, 2024 |
CITADEL ADVISORS LLC | - | - | - | -64,652 | -100.00% | - | Mar 31, 2024 |
SIGMA PLANNING CORP | - | - | - | -12,000 | -100.00% | - | Mar 31, 2024 |
SANDY SPRING BANK | - | - | - | -1,333 | -100.00% | - | Mar 31, 2024 |
TOWER RESEARCH CAPITAL LLC (TRC) | - | - | - | -7,201 | -100.00% | - | Mar 31, 2024 |
ARMISTICE CAPITAL, LLC | - | - | - | -3,207,417 | -100.00% | - | Mar 31, 2024 |
NEWEDGE ADVISORS, LLC | - | - | - | -2 | -100.00% | - | Mar 31, 2024 |
ADVISOR GROUP HOLDINGS, INC. | - | - | - | -968 | -100.00% | - | Mar 31, 2024 |
Moleculin Biotech's largest institutional shareholder is JPMORGAN CHASE & CO, holding 0.00% of the company's total share outstanding, currently valued at -. The top 10 institutional shareholders own together 0.00% of the company.
Institutional Shareholders by % of Total Assets
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
JPMORGAN CHASE & CO | - | - | - | -52 | -100.00% | - | Mar 31, 2024 |
BANK OF AMERICA CORP /DE/ | - | - | - | -138 | -100.00% | - | Mar 31, 2024 |
WELLS FARGO & COMPANY/MN | - | - | - | -229 | -100.00% | - | Mar 31, 2024 |
NORTHERN TRUST CORP | - | - | - | -53,596 | -100.00% | - | Mar 31, 2024 |
STATE STREET CORP | - | - | - | -71,397 | -100.00% | - | Mar 31, 2024 |
VANGUARD GROUP INC | - | - | - | -1,080,122 | -100.00% | - | Mar 31, 2024 |
MORGAN STANLEY | - | - | - | -6,334 | -100.00% | - | Mar 31, 2024 |
ROYAL BANK OF CANADA | - | - | - | -20,148 | -100.00% | - | Mar 31, 2024 |
SCHMIDT P J INVESTMENT MANAGEMENT INC | - | - | - | -29,000 | -100.00% | - | Mar 31, 2024 |
RENAISSANCE TECHNOLOGIES LLC | - | - | - | -129,600 | -100.00% | - | Mar 31, 2024 |
GEODE CAPITAL MANAGEMENT, LLC | - | - | - | -246,670 | -100.00% | - | Mar 31, 2024 |
NORTH STAR INVESTMENT MANAGEMENT CORP. | - | - | - | -250 | -100.00% | - | Mar 31, 2024 |
BLACKROCK INC. | - | - | - | -188,924 | -100.00% | - | Mar 31, 2024 |
CITADEL ADVISORS LLC | - | - | - | -64,652 | -100.00% | - | Mar 31, 2024 |
SIGMA PLANNING CORP | - | - | - | -12,000 | -100.00% | - | Mar 31, 2024 |
SANDY SPRING BANK | - | - | - | -1,333 | -100.00% | - | Mar 31, 2024 |
TOWER RESEARCH CAPITAL LLC (TRC) | - | - | - | -7,201 | -100.00% | - | Mar 31, 2024 |
ARMISTICE CAPITAL, LLC | - | - | - | -3,207,417 | -100.00% | - | Mar 31, 2024 |
NEWEDGE ADVISORS, LLC | - | - | - | -2 | -100.00% | - | Mar 31, 2024 |
ADVISOR GROUP HOLDINGS, INC. | - | - | - | -968 | -100.00% | - | Mar 31, 2024 |
The largest Moleculin Biotech shareholder by % of total assets is JPMORGAN CHASE & CO. The company owns 0.00 shares of Moleculin Biotech (MBRX), representing 0.00% of its total assets.
Institutional Buyers
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
NEWEDGE ADVISORS, LLC | - | - | - | -2 | -100.00% | - | Mar 31, 2024 |
JPMORGAN CHASE & CO | - | - | - | -52 | -100.00% | - | Mar 31, 2024 |
BANK OF AMERICA CORP /DE/ | - | - | - | -138 | -100.00% | - | Mar 31, 2024 |
WELLS FARGO & COMPANY/MN | - | - | - | -229 | -100.00% | - | Mar 31, 2024 |
NORTH STAR INVESTMENT MANAGEMENT CORP. | - | - | - | -250 | -100.00% | - | Mar 31, 2024 |
CVA FAMILY OFFICE, LLC | - | - | - | -500 | -100.00% | - | Mar 31, 2024 |
ADVISOR GROUP HOLDINGS, INC. | - | - | - | -968 | -100.00% | - | Mar 31, 2024 |
SANDY SPRING BANK | - | - | - | -1,333 | -100.00% | - | Mar 31, 2024 |
MORGAN STANLEY | - | - | - | -6,334 | -100.00% | - | Mar 31, 2024 |
TOWER RESEARCH CAPITAL LLC (TRC) | - | - | - | -7,201 | -100.00% | - | Mar 31, 2024 |
SIGMA PLANNING CORP | - | - | - | -12,000 | -100.00% | - | Mar 31, 2024 |
JMAC ENTERPRISES LLC | - | - | - | -13,132 | -100.00% | - | Mar 31, 2024 |
ROYAL BANK OF CANADA | - | - | - | -20,148 | -100.00% | - | Mar 31, 2024 |
SCHMIDT P J INVESTMENT MANAGEMENT INC | - | - | - | -29,000 | -100.00% | - | Mar 31, 2024 |
ATTICUS WEALTH MANAGEMENT, LLC | - | - | - | -50,001 | -100.00% | - | Mar 31, 2024 |
NORTHERN TRUST CORP | - | - | - | -53,596 | -100.00% | - | Mar 31, 2024 |
CITADEL ADVISORS LLC | - | - | - | -64,652 | -100.00% | - | Mar 31, 2024 |
STATE STREET CORP | - | - | - | -71,397 | -100.00% | - | Mar 31, 2024 |
RENAISSANCE TECHNOLOGIES LLC | - | - | - | -129,600 | -100.00% | - | Mar 31, 2024 |
BLACKROCK INC. | - | - | - | -188,924 | -100.00% | - | Mar 31, 2024 |
As of Mar 31 2024, Moleculin Biotech's largest institutional buyer is NEWEDGE ADVISORS, LLC. The company purchased -2.00 stocks of MBRX, valued at -.
Institutional Sellers
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
ARMISTICE CAPITAL, LLC | - | - | - | -3,207,417 | -100.00% | - | Mar 31, 2024 |
VANGUARD GROUP INC | - | - | - | -1,080,122 | -100.00% | - | Mar 31, 2024 |
GEODE CAPITAL MANAGEMENT, LLC | - | - | - | -246,670 | -100.00% | - | Mar 31, 2024 |
BLACKROCK INC. | - | - | - | -188,924 | -100.00% | - | Mar 31, 2024 |
RENAISSANCE TECHNOLOGIES LLC | - | - | - | -129,600 | -100.00% | - | Mar 31, 2024 |
STATE STREET CORP | - | - | - | -71,397 | -100.00% | - | Mar 31, 2024 |
CITADEL ADVISORS LLC | - | - | - | -64,652 | -100.00% | - | Mar 31, 2024 |
NORTHERN TRUST CORP | - | - | - | -53,596 | -100.00% | - | Mar 31, 2024 |
ATTICUS WEALTH MANAGEMENT, LLC | - | - | - | -50,001 | -100.00% | - | Mar 31, 2024 |
SCHMIDT P J INVESTMENT MANAGEMENT INC | - | - | - | -29,000 | -100.00% | - | Mar 31, 2024 |
ROYAL BANK OF CANADA | - | - | - | -20,148 | -100.00% | - | Mar 31, 2024 |
JMAC ENTERPRISES LLC | - | - | - | -13,132 | -100.00% | - | Mar 31, 2024 |
SIGMA PLANNING CORP | - | - | - | -12,000 | -100.00% | - | Mar 31, 2024 |
TOWER RESEARCH CAPITAL LLC (TRC) | - | - | - | -7,201 | -100.00% | - | Mar 31, 2024 |
MORGAN STANLEY | - | - | - | -6,334 | -100.00% | - | Mar 31, 2024 |
SANDY SPRING BANK | - | - | - | -1,333 | -100.00% | - | Mar 31, 2024 |
ADVISOR GROUP HOLDINGS, INC. | - | - | - | -968 | -100.00% | - | Mar 31, 2024 |
CVA FAMILY OFFICE, LLC | - | - | - | -500 | -100.00% | - | Mar 31, 2024 |
NORTH STAR INVESTMENT MANAGEMENT CORP. | - | - | - | -250 | -100.00% | - | Mar 31, 2024 |
WELLS FARGO & COMPANY/MN | - | - | - | -229 | -100.00% | - | Mar 31, 2024 |
As of Mar 31 2024, Moleculin Biotech's biggest institutional seller is ARMISTICE CAPITAL, LLC. The company sold -3.21M shares of MBRX, valued at -.
Institutional New positions
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|
Institutional Sold Out
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
ARMISTICE CAPITAL, LLC | - | - | - | -3,207,417 | -100.00% | - | Mar 31, 2024 |
VANGUARD GROUP INC | - | - | - | -1,080,122 | -100.00% | - | Mar 31, 2024 |
GEODE CAPITAL MANAGEMENT, LLC | - | - | - | -246,670 | -100.00% | - | Mar 31, 2024 |
BLACKROCK INC. | - | - | - | -188,924 | -100.00% | - | Mar 31, 2024 |
RENAISSANCE TECHNOLOGIES LLC | - | - | - | -129,600 | -100.00% | - | Mar 31, 2024 |
STATE STREET CORP | - | - | - | -71,397 | -100.00% | - | Mar 31, 2024 |
CITADEL ADVISORS LLC | - | - | - | -64,652 | -100.00% | - | Mar 31, 2024 |
NORTHERN TRUST CORP | - | - | - | -53,596 | -100.00% | - | Mar 31, 2024 |
ATTICUS WEALTH MANAGEMENT, LLC | - | - | - | -50,001 | -100.00% | - | Mar 31, 2024 |
SCHMIDT P J INVESTMENT MANAGEMENT INC | - | - | - | -29,000 | -100.00% | - | Mar 31, 2024 |
ROYAL BANK OF CANADA | - | - | - | -20,148 | -100.00% | - | Mar 31, 2024 |
JMAC ENTERPRISES LLC | - | - | - | -13,132 | -100.00% | - | Mar 31, 2024 |
SIGMA PLANNING CORP | - | - | - | -12,000 | -100.00% | - | Mar 31, 2024 |
TOWER RESEARCH CAPITAL LLC (TRC) | - | - | - | -7,201 | -100.00% | - | Mar 31, 2024 |
MORGAN STANLEY | - | - | - | -6,334 | -100.00% | - | Mar 31, 2024 |
SANDY SPRING BANK | - | - | - | -1,333 | -100.00% | - | Mar 31, 2024 |
ADVISOR GROUP HOLDINGS, INC. | - | - | - | -968 | -100.00% | - | Mar 31, 2024 |
CVA FAMILY OFFICE, LLC | - | - | - | -500 | -100.00% | - | Mar 31, 2024 |
NORTH STAR INVESTMENT MANAGEMENT CORP. | - | - | - | -250 | -100.00% | - | Mar 31, 2024 |
WELLS FARGO & COMPANY/MN | - | - | - | -229 | -100.00% | - | Mar 31, 2024 |
BANK OF AMERICA CORP /DE/ | - | - | - | -138 | -100.00% | - | Mar 31, 2024 |
JPMORGAN CHASE & CO | - | - | - | -52 | -100.00% | - | Mar 31, 2024 |
NEWEDGE ADVISORS, LLC | - | - | - | -2 | -100.00% | - | Mar 31, 2024 |
Moleculin Biotech's largest sold out institutional shareholder by shares sold is ARMISTICE CAPITAL, LLC, sold -3.21M shares, valued at -, as of undefined.
Moleculin Biotech Mutual Fund Holders
Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
---|---|---|---|---|---|
VANGUARD INDEX FUNDS | 0.00% | 1,525,518 | - | - | Mar 31, 2024 |
VANGUARD INDEX FUNDS | 0.00% | 563,784 | - | - | Mar 31, 2024 |
FIDELITY CONCORD STREET TRUST | 0.00% | 237,035 | - | - | Feb 29, 2024 |
FIDELITY CONCORD STREET TRUST | 0.00% | 223,516 | 1,339 | 0.60% | Feb 29, 2024 |
VANGUARD INSTITUTIONAL INDEX FUNDS | 0.00% | 21,052 | - | - | Mar 31, 2024 |
VANGUARD INSTITUTIONAL INDEX FUNDS | 0.00% | 18,118 | - | - | Mar 31, 2024 |
SCHWAB CAPITAL TRUST | 0.00% | 5,479 | - | - | Jan 31, 2024 |
ALLSPRING MASTER TRUST | 0.00% | 3,253 | - | - | Feb 29, 2024 |
USAA MUTUAL FUNDS TRUST | 0.00% | 9,836 | - | - | Jan 31, 2024 |
USAA MUTUAL FUNDS TRUST | 0.00% | 3,182 | - | - | Jan 31, 2024 |
EQ ADVISORS TRUST | 0.00% | 8,436 | - | - | Mar 31, 2024 |
EQ ADVISORS TRUST | 0.00% | 5,198 | - | - | Mar 31, 2024 |
JOHN HANCOCK VARIABLE INSURANCE TRUST | 0.00% | 2,979 | - | - | Mar 31, 2024 |
JOHN HANCOCK VARIABLE INSURANCE TRUST | 0.00% | 1,608 | - | - | Mar 31, 2024 |
Moleculin Biotech's largest mutual fund holder by % of total assets is "VANGUARD INDEX FUNDS", owning 1.53M shares, compromising 0.00% of its total assets.
Moleculin Biotech Institutional Ownership Trends
Institutional Holdings Trend
Date | Holdings | Change % |
---|---|---|
31 Dec, 23 | 23 | 15.00% |
30 Sep, 23 | 20 | -9.09% |
30 Jun, 23 | 22 | -4.35% |
31 Mar, 23 | 23 | -4.17% |
31 Dec, 22 | 24 | 14.29% |
30 Sep, 22 | 21 | -4.55% |
30 Jun, 22 | 22 | 4.76% |
31 Mar, 22 | 21 | -8.70% |
31 Dec, 21 | 23 | 4.55% |
30 Sep, 21 | 22 | -21.43% |
30 Jun, 21 | 28 | 3.70% |
31 Mar, 21 | 27 | 2600.00% |
31 Dec, 20 | 1 | - |
30 Sep, 20 | 1 | - |
30 Jun, 20 | 1 | - |
31 Mar, 20 | 1 | - |
31 Dec, 19 | 1 | - |
30 Sep, 19 | 1 | - |
30 Jun, 19 | 1 | - |
31 Mar, 19 | 1 | - |
As of 31 Dec 23, 23 institutions are holding Moleculin Biotech's shares, representing an increase of 15.00% compared to the previous quarter.
Shares Outstanding Trend
Date | Shares Outstanding | Change % |
---|---|---|
31 Dec, 23 | 5,183,666 | 140.87% |
30 Sep, 23 | 2,152,050 | -5.84% |
30 Jun, 23 | 2,285,496 | -24.48% |
31 Mar, 23 | 3,026,439 | 1.15% |
31 Dec, 22 | 2,992,164 | 0.26% |
30 Sep, 22 | 2,984,352 | -0.43% |
30 Jun, 22 | 2,997,387 | 1.42% |
31 Mar, 22 | 2,955,289 | -1.48% |
31 Dec, 21 | 2,999,573 | 6.04% |
30 Sep, 21 | 2,828,656 | -3.47% |
30 Jun, 21 | 2,930,396 | 39.22% |
31 Mar, 21 | 2,104,900 | 630109.58% |
31 Dec, 20 | 334 | - |
30 Sep, 20 | 334 | - |
30 Jun, 20 | 334 | - |
31 Mar, 20 | 334 | - |
31 Dec, 19 | 334 | - |
30 Sep, 19 | 334 | - |
30 Jun, 19 | 334 | - |
31 Mar, 19 | 334 | - |
Moleculin Biotech (MBRX) has 5.18M shares outstanding as of 31 Dec 23, up 140.87% compared to the previous quarter.
Institutional Ownership Trend
Date | Ownership % | Change % |
---|---|---|
31 Dec, 23 | 17.39% | 33.10% |
30 Sep, 23 | 7.25% | 11.47% |
30 Jun, 23 | 7.95% | 7.17% |
31 Mar, 23 | 10.53% | 9.62% |
31 Dec, 22 | 10.46% | 9.63% |
30 Sep, 22 | 10.42% | 9.48% |
30 Jun, 22 | 10.49% | 9.81% |
31 Mar, 22 | 10.34% | 8.30% |
31 Dec, 21 | 11.16% | 11.39% |
30 Sep, 21 | 9.90% | 9.33% |
30 Jun, 21 | 10.30% | 11.06% |
31 Mar, 21 | 9.65% | 12604191633.33% |
31 Dec, 20 | 0.00% | 333333.33% |
30 Sep, 20 | 0.00% | 333333.33% |
30 Jun, 20 | 0.00% | 333333.33% |
31 Mar, 20 | 0.00% | 333333.33% |
31 Dec, 19 | 0.00% | 333333.33% |
30 Sep, 19 | 0.00% | 333333.33% |
30 Jun, 19 | 0.00% | 333333.33% |
31 Mar, 19 | 0.00% | - |
As of 31 Dec 23, Moleculin Biotech is held by 17.39% institutional shareholders, representing a 33.10% growth compared to 30 Sep 23.
Institutional Increased Positions Trend
Date | Increased Positions | Change % |
---|---|---|
31 Dec, 23 | 10 | 100.00% |
30 Sep, 23 | 5 | -28.57% |
30 Jun, 23 | 7 | -36.36% |
31 Mar, 23 | 11 | -8.33% |
31 Dec, 22 | 12 | 50.00% |
30 Sep, 22 | 8 | - |
30 Jun, 22 | 8 | -27.27% |
31 Mar, 22 | 11 | -8.33% |
31 Dec, 21 | 12 | 71.43% |
30 Sep, 21 | 7 | -50.00% |
30 Jun, 21 | 14 | -46.15% |
31 Mar, 21 | 26 | - |
31 Dec, 20 | - | - |
30 Sep, 20 | - | - |
30 Jun, 20 | - | - |
31 Mar, 20 | - | - |
31 Dec, 19 | - | - |
30 Sep, 19 | - | - |
30 Jun, 19 | - | -100.00% |
31 Mar, 19 | 1 | - |
10 institutional shareholders have increased their position in MBRX stock as of 31 Dec 23 compared to 5 in the previous quarter (a 100.00% increase).
Institutional Reduced Positions Trend
Date | Reduced Positions | Change % |
---|---|---|
31 Dec, 23 | 4 | - |
30 Sep, 23 | 4 | -20.00% |
30 Jun, 23 | 5 | 66.67% |
31 Mar, 23 | 3 | -40.00% |
31 Dec, 22 | 5 | 66.67% |
30 Sep, 22 | 3 | -62.50% |
30 Jun, 22 | 8 | 166.67% |
31 Mar, 22 | 3 | 50.00% |
31 Dec, 21 | 2 | -66.67% |
30 Sep, 21 | 6 | 500.00% |
30 Jun, 21 | 1 | - |
31 Mar, 21 | - | - |
31 Dec, 20 | - | - |
30 Sep, 20 | - | - |
30 Jun, 20 | - | - |
31 Mar, 20 | - | - |
31 Dec, 19 | - | - |
30 Sep, 19 | - | - |
30 Jun, 19 | - | - |
31 Mar, 19 | - | - |
4 institutional shareholders have reduced their position in MBRX stock as of 31 Dec 23 compared to 4 in the previous quarter (a 0.00% increase).
All Institutional Ownership Trend Data
Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
---|---|---|---|---|---|---|---|---|---|---|
31 Dec, 23 | 23 | 15.00% | 5,183,666 | 140.87% | 17.39% | 33.10% | 10 | 100.00% | 4 | - |
30 Sep, 23 | 20 | -9.09% | 2,152,050 | -5.84% | 7.25% | 11.47% | 5 | -28.57% | 4 | -20.00% |
30 Jun, 23 | 22 | -4.35% | 2,285,496 | -24.48% | 7.95% | 7.17% | 7 | -36.36% | 5 | 66.67% |
31 Mar, 23 | 23 | -4.17% | 3,026,439 | 1.15% | 10.53% | 9.62% | 11 | -8.33% | 3 | -40.00% |
31 Dec, 22 | 24 | 14.29% | 2,992,164 | 0.26% | 10.46% | 9.63% | 12 | 50.00% | 5 | 66.67% |
30 Sep, 22 | 21 | -4.55% | 2,984,352 | -0.43% | 10.42% | 9.48% | 8 | - | 3 | -62.50% |
30 Jun, 22 | 22 | 4.76% | 2,997,387 | 1.42% | 10.49% | 9.81% | 8 | -27.27% | 8 | 166.67% |
31 Mar, 22 | 21 | -8.70% | 2,955,289 | -1.48% | 10.34% | 8.30% | 11 | -8.33% | 3 | 50.00% |
31 Dec, 21 | 23 | 4.55% | 2,999,573 | 6.04% | 11.16% | 11.39% | 12 | 71.43% | 2 | -66.67% |
30 Sep, 21 | 22 | -21.43% | 2,828,656 | -3.47% | 9.90% | 9.33% | 7 | -50.00% | 6 | 500.00% |
30 Jun, 21 | 28 | 3.70% | 2,930,396 | 39.22% | 10.30% | 11.06% | 14 | -46.15% | 1 | - |
31 Mar, 21 | 27 | 2600.00% | 2,104,900 | 630109.58% | 9.65% | 12604191633.33% | 26 | - | - | - |
31 Dec, 20 | 1 | - | 334 | - | 0.00% | 333333.33% | - | - | - | - |
30 Sep, 20 | 1 | - | 334 | - | 0.00% | 333333.33% | - | - | - | - |
30 Jun, 20 | 1 | - | 334 | - | 0.00% | 333333.33% | - | - | - | - |
31 Mar, 20 | 1 | - | 334 | - | 0.00% | 333333.33% | - | - | - | - |
31 Dec, 19 | 1 | - | 334 | - | 0.00% | 333333.33% | - | - | - | - |
30 Sep, 19 | 1 | - | 334 | - | 0.00% | 333333.33% | - | - | - | - |
30 Jun, 19 | 1 | - | 334 | - | 0.00% | 333333.33% | - | -100.00% | - | - |
31 Mar, 19 | 1 | - | 334 | - | 0.00% | - | 1 | - | - | - |
Moleculin Biotech Insider Shareholders Trades
Open Market Insider Trades
Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
---|
Open Market Insider Buys
Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
---|
Insider Sells
All Insider Owners Trades
The last insider sell of Moleculin Biotech's stock was made by KLEMP WALTER V on Jul 05 2024, selling 982 shares at - per share (valued at -).
Moleculin Biotech Insider Ownership Trends
All Insider Trades Trend
Date | Buy | Sell | Buy/Sell Ratio |
---|---|---|---|
Q2 2024 | 5 | 10 | 50.00% |
Q4 2023 | 3 | - | - |
Q3 2023 | 2 | 4 | 50.00% |
Q2 2023 | 16 | 10 | 160.00% |
Q4 2022 | 4 | - | - |
Q3 2022 | 2 | 8 | 25.00% |
Q2 2022 | 22 | 4 | 550.00% |
Q1 2022 | 1 | - | - |
Q3 2021 | 2 | 4 | 50.00% |
Q2 2021 | 9 | - | - |
Q4 2020 | 1 | - | - |
Q3 2020 | 6 | 2 | 300.00% |
Q2 2020 | 3 | - | - |
Q3 2019 | 7 | - | - |
Q2 2019 | 3 | - | - |
Q2 2018 | 7 | - | - |
Q4 2017 | 3 | - | - |
Q3 2017 | 3 | 2 | 150.00% |
Q2 2017 | 4 | - | - |
Q3 2016 | 4 | - | - |
5 total buy trades, and 10 total sell trades (buy/sell ratio of 0.50%) were made by Moleculin Biotech's insiders, as of Q2 2024.
Open Market Insider Trades Trend
Date | Buy | Sell | Buy/Sell Ratio |
---|---|---|---|
Q2 2024 | - | - | - |
Q4 2023 | 3 | - | - |
Q3 2023 | - | - | - |
Q2 2023 | - | - | - |
Q4 2022 | 4 | - | - |
Q3 2022 | - | - | - |
Q2 2022 | - | - | - |
Q1 2022 | - | - | - |
Q3 2021 | - | - | - |
Q2 2021 | - | - | - |
Q4 2020 | - | - | - |
Q3 2020 | - | - | - |
Q2 2020 | - | - | - |
Q3 2019 | - | - | - |
Q2 2019 | - | - | - |
Q2 2018 | - | - | - |
Q4 2017 | - | - | - |
Q3 2017 | - | 2 | - |
Q2 2017 | 4 | - | - |
Q3 2016 | - | - | - |
As of Q2 2024, Insider owners conducted 0 open market buy trades and 0 open market sell trades of Moleculin Biotech's stocks.
Moleculin Biotech Peer Ownership
Ticker | Company |
---|---|
PMVP | PMV Pharmaceuticals, Inc. |
CFRX | ContraFect Corporation |
PULM | Pulmatrix, Inc. |
NXTC | NextCure, Inc. |
CYCC | Cyclacel Pharmaceuticals, Inc. |
IKT | Inhibikase Therapeutics, Inc. |
BPTH | Bio-Path Holdings, Inc. |
CAPR | Capricor Therapeutics, Inc. |
DFFN | CervoMed Inc. |
AKTX | Akari Therapeutics, Plc |
ANTX | AN2 Therapeutics, Inc. |
VRAX | Virax Biolabs Group Limited |
ALLR | Allarity Therapeutics, Inc. |
ANEB | Anebulo Pharmaceuticals, Inc. |
ONTX | Traws Pharma, Inc. |
ATXI | Avenue Therapeutics, Inc. |
CBIO | Gyre Therapeutics, Inc. |
MBRX Ownership FAQ
Who Owns Moleculin Biotech?
Moleculin Biotech is owned by institutional shareholders (17.39%), insiders (4.33%), and public (78.28%). The largest institutional shareholder of Moleculin Biotech is JPMORGAN CHASE & CO (0% of total shares) and the top mutual fund owner is VANGUARD INDEX FUNDS (0.00% of total shares).
Who are the major institutional shareholders of Moleculin Biotech?
Moleculin Biotech's major institutional shareholders are JPMORGAN CHASE & CO, BANK OF AMERICA CORP /DE/, WELLS FARGO & COMPANY/MN, NORTHERN TRUST CORP, and STATE STREET CORP. The top five shareholders own together 0% of the company's share outstanding.
How many Moleculin Biotech shareholders are there?
As of Dec 2023, there are 23 institutional shareholders of Moleculin Biotech.
What percentage of Moleculin Biotech is owned by JPMORGAN CHASE & CO?
JPMORGAN CHASE & CO owns 0 shares of Moleculin Biotech, representing 0% of the company's total shares outstanding, valued at $0 (as of Mar 2024).
What percentage of Moleculin Biotech is owned by BANK OF AMERICA CORP /DE/?
As of Mar 2024, BANK OF AMERICA CORP /DE/ holds 0 shares of Moleculin Biotech (MBRX), compromising 0% of the company, valued at $0.
What percentage of Moleculin Biotech is owned by WELLS FARGO & COMPANY/MN?
WELLS FARGO & COMPANY/MN is the third largest holder of Moleculin Biotech. The company owns 0 of the company's shares outstanding (worth $0).